Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06479863 · ClinicalTrials.gov registry record · Early Phase 1
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
A Early Phase 1 study of Idiopathic Inflammatory Myopathies and Sporadic Inclusion Body Myositis (sIBM), sponsored by Austin Neuromuscular Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06479863 is a Early Phase 1 study of Idiopathic Inflammatory Myopathies and Sporadic Inclusion Body Myositis (sIBM) that is actively recruiting participants, run by Austin Neuromuscular Center. The registered enrollment target is 10 participants, below the 207-participant average among 7 other Idiopathic Inflammatory Myopathies trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06479863, a Early Phase 1 study of Idiopathic Inflammatory Myopathies and Sporadic Inclusion Body Myositis (sIBM), is actively recruiting participants, sponsored by Austin Neuromuscular Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
Conditions Studied
Interventions
- COMBINATION_PRODUCT Pozelimab/Cemdisiran
Study Locations (2)
Texas
- Austin Neuromuscular Center - Austin
- Austin Neuromuscular Center - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2027-08-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06479863
The ClinicalTrials.gov registry entry for NCT06479863 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 207-participant average among 7 other Idiopathic Inflammatory Myopathies trials with a reported enrollment target (95% lower). The listed sponsor is Austin Neuromuscular Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Idiopathic Inflammatory Myopathies appearing as the primary indexed condition, and to 1 intervention - of which Pozelimab/Cemdisiran is the first listed.
NCT06479863 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06479863 about?
NCT06479863 is a clinical study titled "Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis". To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
What is the current status of trial NCT06479863?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-08-08. Estimated completion is 2027-08-30.
What conditions does trial NCT06479863 study?
This clinical trial studies the following conditions: Idiopathic Inflammatory Myopathies, Sporadic Inclusion Body Myositis (sIBM).
What interventions are being tested in trial NCT06479863?
The interventions under investigation include: Pozelimab/Cemdisiran (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06479863?
This trial is sponsored by Austin Neuromuscular Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06479863 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Inflammatory Myopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
RECRUITING · Phase 2
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
RECRUITING · Phase 1
-
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
ACTIVE NOT RECRUITING · Phase 1
-
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Idiopathic Inflammatory Myopathies
All registered trials for this condition
Sporadic Inclusion Body Myositis (sIBM)
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.